BioCentury | Apr 5, 2012
Distillery Therapeutics

Indication: Cancer

...by the Cancer Research UK group based on a patent application filed by the company. Epi Pharmaceuticals Inc....
BioCentury | Apr 5, 2012
Targets & Mechanisms

AML takes LSD1

...At least four biotech companies have LSD1 inhibitor programs. In addition to Oryzon and Salarius, Epi Pharmaceuticals Inc....
...and Institutions Mentioned Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Cancer Research UK , London, U.K. Epi Pharmaceuticals Inc....
BioCentury | Mar 22, 2012
Distillery Therapeutics

Indication: Cancer

...Tranylcypromine is a generic monoamine oxidase inhibitor (MAOI) marketed to treat depression. Oryzon Genomics and Epi Pharmaceuticals Inc....
Items per page:
1 - 3 of 3
BioCentury | Apr 5, 2012
Distillery Therapeutics

Indication: Cancer

...by the Cancer Research UK group based on a patent application filed by the company. Epi Pharmaceuticals Inc....
BioCentury | Apr 5, 2012
Targets & Mechanisms

AML takes LSD1

...At least four biotech companies have LSD1 inhibitor programs. In addition to Oryzon and Salarius, Epi Pharmaceuticals Inc....
...and Institutions Mentioned Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Cancer Research UK , London, U.K. Epi Pharmaceuticals Inc....
BioCentury | Mar 22, 2012
Distillery Therapeutics

Indication: Cancer

...Tranylcypromine is a generic monoamine oxidase inhibitor (MAOI) marketed to treat depression. Oryzon Genomics and Epi Pharmaceuticals Inc....
Items per page:
1 - 3 of 3